Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 12/20 | 0.64 |
| ▸ | CA2 | P00918 | 8/20 | 0.43 |
| ▸ | CA1 | P00915 | 6/20 | 0.43 |
| ▸ | CA7 | P43166 | 6/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.43 |
| ▸ | CA4 | P22748 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | CA3 | P07451 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7595316 | 0.99 | PTPN1 (0.66) | PTPN1CA2CA1CA7CA12 | |
| SCHEMBL7663135 | 0.92 | PTPN1 (0.73) | PTPN1CA2CA1CA7CA12 | |
| SCHEMBL7659253 | 0.83 | PTPN1 (0.70) | PTPN1PTPN2PTPRC | |
| SCHEMBL7189478 | 0.82 | PTPN1 (0.65) | PTPN1CA2CA1CA7CA12 | |
| SCHEMBL7189798 | 0.82 | PTPN1 (0.62) | PTPN1CA2CA1CA7CA12 | |
| SCHEMBL7188773 | 0.82 | PTPN1 (0.73) | PTPN1CA2CA1CA12CA9 | |
| SCHEMBL7182937 | 0.81 | PTPN1 (0.58) | PTPN1PTPN2PTPRC | |
| SCHEMBL7197816 | 0.81 | PTPN1 (0.52) | PTPN1PTPN2PTPRC | |
| SCHEMBL7183004 | 0.81 | PTPN1 (0.65) | PTPN1PTPN2PTPRC | |
| SCHEMBL7599748 | 0.81 | PTPN1 (0.65) | PTPN1PTPN2PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6498151-B2 | PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-12-24 | — | — | US | disclosed |
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | PTPRF, PTPRS, PTPRO | PTPN1 13/4885CA2 2577/4885CA1 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.